MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma
Christine E Ryan, Matthew S Davids, Richard Hermann, Mina Shahkarami, Juliana Biondo, Sarang Abhyankar, Hasan Alhasani, Jeff P Sharman, Anthony R Mato, Lindsey E Roeker, Christine E Ryan, Matthew S Davids, Richard Hermann, Mina Shahkarami, Juliana Biondo, Sarang Abhyankar, Hasan Alhasani, Jeff P Sharman, Anthony R Mato, Lindsey E Roeker
Abstract
Here we describe the rationale and design of MAJIC, a phase III, prospective, multicenter, randomized trial comparing the combination of the BTK inhibitor acalabrutinib plus the BCL2 inhibitor venetoclax versus the combination of venetoclax plus obinutuzumab as frontline treatment for chronic lymphocytic leukemia or small lymphocytic lymphoma. In both treatment arms, disease response (assessed by International Workshop on Chronic Lymphocytic Leukemia criteria) and minimal residual disease will be used to guide therapy duration, with all patients ultimately discontinuing treatment after a maximum of 2 years. The primary end point is progression-free survival. Key secondary end points include rates of undetectable minimal residual disease, overall response and overall survival. This study will address key unanswered questions in frontline chronic lymphocytic leukemia/small lymphocytic lymphoma therapy by investigating the optimal duration of finite treatment and identifying the optimal venetoclax doublet regimen.
Trial registration: ClinicalTrials.gov NCT05057494.
Keywords: CLL; MRD; SLL; acalabrutinib; finite therapy; frontline therapy; obinutuzumab; treatment-naïve; venetoclax.
Source: PubMed